Skip to main content

Prostate Cancer: Medical Treatments

Volume 506: debated on Wednesday 24 February 2010

To ask the Secretary of State for Health how many people with a diagnosis of prostate cancer were recorded as having received treatment by (a) watchful waiting, (b) active surveillance, (c) radical prostatectomy, (d) laparoscopic prostatectomy, (e) robotic prostatectomy, (f) low-dose rate brachytherapy, (g) high-dose rate brachytherapy, (h) cryotherapy, (i) external beam radiotherapy, (j) hormone therapy, (k) high intensity ultrasound, (l) chemotherapy, (m) bisphosphonates and (n) another method in each primary care trust commissioning area of responsibility in each year since 1997-98. (317710)

This information is not held in the requested format. We are not able to provide figures relating to watchful waiting, active surveillance, radical prostatectomy and bisphosphonates, as these are not captured in Office of Population Censuses and Surveys (OPCS)-4 codes.

We have provided a count of finished consultant episodes where the primary diagnosis was prostate cancer and this information has been placed in the Library.

To ask the Secretary of State for Health how much has been spent on hormonal therapy prescriptions for prostate cancer in (a) England, (b) each primary care trust area and (c) each constituency since 2007. (317715)

The information requested has been placed in the Library, apart from constituency information, which is not collected centrally.

The tables provide the net ingredient cost of prescription items dispensed in the community by primary care trust (PCT) and nationally. Information on usage in hospitals is available and has been included in the response for England but is not available at PCT level.